BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...

BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...